Sibold William John

President and CEO, DirectorMADRIGAL PHARMACEUTICALS, INC. (MDGL) · full profile →Form 4 · filed Jul 21, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.4M
Net Open-Market Flow
-$1.4M
Transactions
12
11 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 20, 2026Sell(S)280$555.05$155K209K
Jul 20, 2026Sell(S)140$542.75$76K212K
Jul 20, 2026Sell(S)110$543.79$60K212K
Jul 20, 2026Sell(S)545$544.71$297K211K
Jul 20, 2026Sell(S)275$545.71$150K211K
Jul 20, 2026Sell(S)269$547.08$147K210K
Jul 20, 2026Sell(S)680$547.70$372K210K
Jul 20, 2026Sell(S)47$548.87$26K210K
Jul 20, 2026Sell(S)153$550.01$84K210K
Jul 20, 2026Sell(S)1$550.72$551210K
Jul 17, 2026Option exercise(M)50K212K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 17, 2026Option exercise(M)50K$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-048919) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.